Olix Pharmaceuticals

Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases.

placeSuwon-si, Gyeonggi-do, South Korea calendar_todayFounded 2010 groups72 employees language olixpharma.com

Registered entities

Innovation

27 patent families (12 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace steady. Cited 2,215 times.

YearFilings
20161
20176
20188
201910
202011
20217
20228
20236
202410
20256
20266

Social engagement

Social engagement: 5.3K social following, 7 posts in the last 12 months — around the industry typical range.

Investor mix

16 investors on record.

Investor typeCountShare
Venture capital1169%
Private equity425%
Other / undisclosed16%

Recent activity

17 Jun 2026
Event
BIO International Convention 2026 (BIO USA)
16 Jun 2026
Partnership
Vect-Horus
18 May 2026
Event
NATi RNA Symposium 2026
Coming soon